BRUSSELS, Jan 23 (Reuters) – Belgian supermarket group
Delhaize reported broadly unchanged fourth-quarter
revenue on Thursday as sales growth in both the United States
and Belgium were neutralised by a weaker dollar.
The group, which has about 3,500 stores worldwide and makes
about 60 percent of its revenue in the United States, said
revenue inched up by 0.1 percent, or 3.0 percent at identical
exchange rates, to 5.34 billion euros ($7.24 billion).
HONG KONG/BRUSSELS (Reuters) – Anheuser-Busch InBev SA, the world’s biggest brewer, agreed to buy back South Korea’s Oriental Brewery Co Ltd (OB) for $5.8 billion including debt, returning to a large Asian market at a time of strong industry growth across the region.
The sale by KKR & Co and Affinity Equity Partners will be Asia’s biggest ever for private equity, excluding flotations, and rewards them with returns of more than five times their investment.
BRUSSELS (Reuters) – Belgian mobile telephone operator Mobistar set cable operators a six-month deadline on Friday to open up their networks, allowing it to start its own television and fixed-line phone and internet services by the end of the year.
Mobistar said in a statement it had paid 600,000 euros ($816,100) to Telenet, which is active in the northern region of Flanders, and the same amount to southern Belgian cable operator Brutele-Tecteo.
BRUSSELS (Reuters) – Dutch grocer Ahold (AHLN.AS: Quote, Profile, Research, Stock Buzz) reported a steeper-than-expected decline in fourth-quarter sales, as the U.S. food market contracted and customers in the Netherlands spent less per visit to its shops.
The group, which makes three-fifths of its revenue in the United States, said on Thursday sales fell by 4.2 percent, or 1.1 percent at constant exchange rates, to 7.47 billion euros ($10.2 billion).
BRUSSELS (Reuters) – Belgian medical researchers have succeeded in repairing bones using stem cells from fatty tissue, with a new technique they believe could become a benchmark for treating a range of bone disorders.
The team at the Saint Luc university clinic hospital in Brussels have treated 11 patients, eight of them children, with fractures or bone defects that their bodies could not repair, and a spin-off is seeking investors to commercialize the discovery.
BRUSSELS, Jan 12 (Reuters) – Year-end U.S. shopping and
manufacturing output figures and a Friday credit-rating blitz in
Europe are expected to set the tone this week, showing the
global economy’s uneven recovery remains on track.
Last week ended on a jarring note, with data showing U.S.
employers hired the fewest number of workers in almost three
years in December.
BRUSSELS, Dec 17 (Reuters) – Genetically modified crops,
chlorine-washed chicken, beef quotas and a fight over who can
call Greek-style cheese ‘feta’ all block the way towards the
world’s largest free-trade deal.
U.S. and European Union negotiators will determine a list of
sticking points this week in Washington during their third round
of talks, and food issues are expected to be chief among them.
BRUSSELS, Nov 28 (Reuters) – Belgian biotech company Ablynx
is hopeful of finding partners to develop its
therapies in emerging markets next year, its chief executive
told Reuters on Thursday.
Belgium’s biotech industry has expanded in the past decade
because of tax breaks covering patent income and research
workers’ salaries, and a string of companies have listed on the
Brussels stock exchange.
BRUSSELS, Nov 27 (Reuters) – Belgian chemicals group Solvay
has cut its profit forecasts for the coming years,
blaming a sluggish economic recovery – particularly in Europe -
and the planned divestment of lower margin businesses.
The company, traditionally a maker of base chemicals such as
soda ash, used for making glass, said on Wednesday it expected
core earnings (REBITDA) to rise to between 2.3 and 2.5 billion
euros ($3.1-$3.4 billion) in 2016.
BRUSSELS, Nov 21 (Reuters) – Belgian radiology company IBA
sees 2014 as a year of major transition which could
lead to an acceleration of sales of its cancer-fighting proton
The global market leader has been selling its systems to
major hospitals and clinics for more than a decade, but has been
hampered by the scale of the investment required for each
facility and recently launched a more compact product, called